Pharmaceutical - Ranbaxy Laboratories, Pharmaceutical

Filter

Popular Filters

Ranbaxy to distribute Cipher’s isotretinoin product in Brazil

25-07-2014

Canada’s Cipher Pharmaceuticals has signed a definitive distribution and supply agreement with India’s…

BrazilCipher PharmaceuticalsDermatologicalsIsotretinoinLicensingPharmaceuticalRanbaxy Laboratories

Ranbaxy reports loss for March fiscal quarter

Ranbaxy reports loss for March fiscal quarter

12-05-2014

Indian drug maker Ranbaxy Laboratories, majority-owned by Japan’s Daiichi Sankyo and subject of an…

FinancialIndiaPharmaceuticalRanbaxy Laboratories

Generic pains for AstraZeneca exacerbated by Indian drugmakers

Generic pains for AstraZeneca exacerbated by Indian drugmakers

06-04-2014

Indian generic companies are taking aim at mega blockbusters, and AstraZeneca, the $25.7 billion pharmaceutical…

Asia-PacificAstraZenecaDr Reddy's LaboratoriesFinancialGastro-intestinalsGenericsIndiaMarkets & MarketingNexiumPharmaceuticalPulmicortRanbaxy LaboratoriesRespiratory and PulmonarySymbicortUSAVimovo

India’s IPAB upholds Pfizer’s Detrol patent

India’s IPAB upholds Pfizer’s Detrol patent

27-03-2014

In a positive development for US drug giant Pfizer, India's Intellectual Property Appellate Board (IPAB)…

Asia-PacificDetrolGenito-urinaryIndiaPatentsPfizerPharmaceuticalRanbaxy Laboratories

Ranbaxy recalls Lipitor generic over dose error

Ranbaxy recalls Lipitor generic over dose error

10-03-2014

India’s largest drugmaker Ranbaxy Laboratories (BSE: 500359) has recalled more than 64,000 bottles…

Atorvastatin CalciumCardio-vascularIndiaLipitorPharmaceuticalRanbaxy LaboratoriesRegulationUSA

India and the USA need to collaborate

India and the USA need to collaborate

14-02-2014

Here's our take on the week's top stories.

IndiaPharmaceuticalRanbaxy LaboratoriesRegulationUSAWockhardt

Daiichi Sankyo sales up while Ranbaxy sales decline

Daiichi Sankyo sales up while Ranbaxy sales decline

01-11-2013

Daiichi Sankyo has released results for the fiscal period April 1 to September 30, showing net sales…

Asia-PacificDaiichi SankyoFinancialPharmaceuticalRanbaxy Laboratories

EU Commission fines Lundbeck and other Pharmas over "pay-for-delay" deals

19-06-2013

In a much awaited decision following its investigations of patent settlements (or pay-for-delay deals)…

ActaviscitalopramEuropeFinancialGenericsLegalLundbeckMerck KGaAMylan LaboratoriesNeurologicalPatentsPharmaceuticalRanbaxy Laboratories

Daiichi Sankyo and Ranbaxy to launch branded generics in Brazil

21-04-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) and its majority (64%)-owned Indian affiliate Ranbaxy…

Daiichi SankyoGenericsMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSouth America

Daiichi Sankyo sets out five-year plan to overcome Olmetec patent expiry

25-03-2013

Japanese drug major Daiichi Sankyo (TYO: 4568) has announced a new five-year Business Plan, which will…

Daiichi SankyoFinancialolmesartanOlmetecPatentsPharmaceuticalRanbaxy Laboratories

Indian pharmaceuticals market led by Ranbaxy in terms of revenue

31-01-2013

The Indian pharmaceutical market is the world's third-largest in terms of volume and stands 14th in terms…

Asia-PacificBioconBiotechnologyGenericsMarkets & MarketingPanacea BiotecPharmaceuticalRanbaxy LaboratoriesSerum Institute of India

Daiichi Sankyo and Ranbaxy combine business operations in Thailand

16-01-2013

Japanese pharma major Daiichi Sankyo (TYO: 4568) and its 64%-owned affiliate Ranbaxy Laboratories (AB:…

Asia-PacificDaiichi SankyoGenericsManagementMarkets & MarketingPharmaceuticalRanbaxy Laboratories

Ranbaxy Labs' Absorica debuts in USA

27-11-2012

Indian drugmaker Ranbaxy Laboratories (AB: BO), which is majority owned by Japan's Daiichi Sankyo, said…

AbsoricaCipher PharmaceuticalsDaiichi SankyoDermatologicalsGalephar Pharmaceutival ResearchGenericsMarkets & MarketingNorth AmericaPharmaceuticalRanbaxy Laboratories

Gilead partners to provide low-cost emtricitabine-based ARVs in developing countries

03-08-2012

Gilead Sciences (Nasdaq: GILD), together with Mylan Laboratories, Ranbaxy Laboratories and Strides Arcolab…

Anti-viralsBiotechnologyEmtricitabineGilead SciencesGlobalLicensingMylan LaboratoriesPharmaceuticalPricingProductionRanbaxy LaboratoriesStrides Arcolab

Daiichi Sankyo and Ranbaxy debut hybrid business model in Venezuela

20-06-2012

Japanese drug major Daiichi Sankyo (TYO: 4568) announced that its Daiichi Sankyo Venezuela unit would…

Daiichi SankyoGenericsMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSouth America

Ranbaxy gains US FDA approval for Absorica

29-05-2012

India's largest drugmaker Ranbaxy Laboratories (AB: BO) has received approval from the US Food and Drug…

AbsoricaCipher PharmaceuticalsDermatologicalsIsotretinoinNorth AmericaPharmaceuticalRanbaxy LaboratoriesRegulation

Ranbaxy debuts first Indian-developed malaria drug, Synriam

27-04-2012

Indian drug major Ranbaxy (AB: B) said yesterday - coinciding with World Malaria Day - that it is "opening…

Asia-PacificDaiichi SankyoMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSynriamTropical diseases

Daiichi Sankyo and Ranbaxy launch Sevikar in Romania

19-04-2012

Japanese drug major Daiichi Sankyo (TYO: 4568) and its majority-owned Indian subsidiary Ranbaxy Laboratories…

Cardio-vascularDaiichi SankyoEuropeGenericsMarkets & MarketingPharmaceuticalRanbaxy LaboratoriesSevikar

Ranbaxy signs consent decree with US FDA over production practices

22-12-2011

India’s largest drugmaker Ranbaxy Laboratories (RANB: BO), which is 64% owned by Japan’s Daiichi…

Daiichi SankyoFinancialGenericsLegalNorth AmericaPharmaceuticalRanbaxy LaboratoriesRegulation

Watson and Ranbaxy kick off genericization of Lipitor, launching their approved copies in USA

01-12-2011

US generic drug major Watson Pharmaceuticals (NYSE: WPI) was the first to confirm yesterday that it has…

atorvastatinCardio-vascularGenericsLipitorMarkets & MarketingNorth AmericaPfizerPharmaceuticalRanbaxy LaboratoriesTeva Pharmaceutical IndustriesWatson Pharmaceuticals

Back to top